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http://www.biomedcentral.com/1472-6947/13/65RESEARCH ARTICLE Open AccessCriteria for assessing high-priority drug-drug
interactions for clinical decision support in
electronic health records
Shobha Phansalkar1,2*, Amrita Desai1, Anish Choksi5, Eileen Yoshida1, John Doole1, Melissa Czochanski1,
Alisha D Tucker1, Blackford Middleton1,2, Douglas Bell3,4 and David W Bates1,2Abstract
Background: High override rates for drug-drug interaction (DDI) alerts in electronic health records (EHRs) result in
the potentially dangerous consequence of providers ignoring clinically significant alerts. Lack of uniformity of
criteria for determining the severity or validity of these interactions often results in discrepancies in how these are
evaluated. The purpose of this study was to identify a set of criteria for assessing DDIs that should be used for the
generation of clinical decision support (CDS) alerts in EHRs.
Methods: We conducted a 20-year systematic literature review of MEDLINE and EMBASE to identify characteristics
of high-priority DDIs. These criteria were validated by an expert panel consisting of medication knowledge base
vendors, EHR vendors, in-house knowledge base developers from academic medical centers, and both federal and
private agencies involved in the regulation of medication use.
Results: Forty-four articles met the inclusion criteria for assessing characteristics of high-priority DDIs. The panel
considered five criteria to be most important when assessing an interaction- Severity, Probability, Clinical Implications of
the interaction, Patient characteristics, and the Evidence supporting the interaction. In addition, the panel identified
barriers and considerations for being able to utilize these criteria in medication knowledge bases used by EHRs.
Conclusions: A multi-dimensional approach is needed to understanding the importance of an interaction for inclusion
in medication knowledge bases for the purpose of CDS alerting. The criteria identified in this study can serve as a first
step towards a uniform approach in assessing which interactions are critical and warrant interruption of a provider’s
workflow.
Keywords: Clinical decision support, Drug-drug interaction, Medication-related decision support system, Electronic
health record, AlertsBackground
Medication-related decision support (MDS) alerts gener-
ated at the point of prescribing have the potential to pre-
vent adverse drug events (ADEs) and improve patient
safety [1]. Despite their potential benefit, these alerts are
often ignored [2] as a result of ‘alert fatigue’ [3]. Alert fa-
tigue is the consequence of receiving a high volume of* Correspondence: sphansalkar@partners.org
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distribution, and reproduction in any mediumalerts whereby users start ignoring critical alerts along
with those that may be clinically insignificant [4-7].
Studies evaluating the reasons for these high override
rates have found that the interactions for which the
alerts are generated often lack clinical significance and
may also have inadequate literature evidence supporting
their validity [4-6]. Previous studies have identified over-
alerting as a barrier to EHRs achieving their full poten-
tial in improving patient safety [6,7].
The Stage 1 Meaningful Use (HIT) certification stan-
dards required the implementation of drug-drug and
drug allergy checking in EHRs [8]. In Stage 2, the rec-
ommendation was for EHRs to employ interactiontral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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for the provider to refine DDI rules. In Stage 3, the
criteria may well call for a nationally endorsed lists of
high priority DDIs to be implemented in EHRs [9]. A
major limitation in being able to develop such a list
of high-priority DDIs was the lack of consensus on
criteria that should be used to evaluate these interac-
tions in order to prioritize them as clinically signifi-
cant. While the significance of an interaction is
largely dependent on the clinical context in which it
presents itself, such as the patient’s status, medication
profile, etc., there are a number of criteria that need
to be evaluated when an interaction is considered for
inclusion in a medication knowledge base. Currently,
knowledge base vendors and in-house curators of
knowledge bases employ disparate criteria, with varied
relevance, resulting in a lack of consensus and low
overlap on what are considered the most severe DDIs
[10]. We employed a mixed approach, first, assessing
the state-of-the-art in terms of DDI assessment as de-
scribed in the literature. Second, we validated these
criteria with a panel of experts, both from the con-
tent and implementation perspective to assess both
the validity and the feasibility of utilizing these cri-
teria for the assessment of DDIs in medication know-
ledge bases used in EHRs.
In 2010, the Office of the National Coordinator for
Health Information Technology (ONC-HIT) commis-
sioned an effort to address the challenges of alert burden
and its impact on EHR adoption [11]. The larger effort
was aimed at identifying key interactions that should
be implemented in knowledge bases to reduce alert fa-
tigue [12]. A first step in identifying these interactions
was to assess what criteria these interactions need to
meet in order to be deemed as high severity DDIs. The
specific goal of this study is to describe important cri-
teria for choosing interactions to include for CDS in
an EHR.Methods
We conducted a 20-year systematic literature review,
from 1990 to 2010 of two bibliographic databases,
MEDLINE and EMBASE, in order to identify articles
that described characteristics of high-priority DDIs. The
criteria identified from the review were then validated by
a panel of subject matter experts (SMEs) representing
various perspectives in the domain of medication deci-
sion support in EHRs - EHR vendors, academic medical
centers, and regulatory agencies, such as the Food and
Drug Administration and professional organizations such
as the American Society of Health-System Pharmacists.
No human subjects or data from human subjects was used
in this study.Systematic literature review
Two literature databases, MEDLINE and EMBASE were
searched using keywords and MeSH terms for relevant
studies on medication related decision support in clinical
information systems. A detailed list of terms employed
for this search is listed in Figure 1. The search was re-
stricted to the time period of January 1990 to December
2010. We looked for the presence of specific keywords
and MeSH terms in two categories in the title, abstract,
and body of the articles. The categories employed were
as follows:
i) Category (A) consisted of terms that described a
clinical information system or electronic medical
record.
ii) Category (B) consisted of terms referring to
medication-related decision support interventions
including mechanisms (alerts, warnings, reminders,
etc.) of generating MDS.
Using the keywords identified in categories A and B
we identified 280,221 and 588 articles respectively. An
intersection of these two sets of terms [A AND B]
resulted in 192 articles which contained concepts from
both sets of keywords. We reviewed the abstracts for
these articles and identified 41 articles that matched our
inclusion criteria. In addition, we looked at the bibliog-
raphies of “relevant articles”, which yielded 15 articles
and a previously conducted systematic review on the
topic of alert fatigue [4] identified 22 articles resulting in
a total of 78 relevant articles. After removing duplicates,
we had a total of 67 articles which were independently
reviewed. Following a comprehensive review, of these ar-
ticles, reviewers identified 43 articles that matched our
criteria. Common reasons for excluding articles at this
stage included: articles on e-prescribing and use of
CPOE in various other clinical settings, use of CPOE in
patient care management, treatment protocols/guide-
lines in relation to CDSS, disease management & Drug
treatment comparisons, clinical drug trials & pharmaco-
kinetic/pharmacodynamic studies, and cost effective
analysis of treatment options. See Additional file 1 for a
list of the 43 articles reviewed. Two reviewers assessed
all articles that matched these inclusion criteria to deter-
mine relevance. Following this first round of elimination,
a team of five reviewers, consisting of 3 pharmacists, 1
physician and 1 human factors expert, all with expertise
in clinical information systems, reviewed the relevant
articles to extract criteria for high priority DDIs. Each
article was reviewed by at least three reviewers, one of
whom (SP) served as a moderator to resolve differences
in the criteria extracted by the primary reviewers. Each
reviewer independently extracted criteria from relevant
studies on how the evidence on DDIs could be filtered
PP
Figure 1 Methodology for extracting relevant articles in the systematic review process. Provides an illustration of the methodology used
in conducting the systematic review. The review focused on extracting articles on medication-related decision support in electronic
health records.
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Expert panel discussions
Experts with a diverse background in the development,
maintenance and implementation of medication-related
decision support in EHRs were invited to participate
on a panel to validate the criteria and barriers in
implementing a list of high priority DDIs. Owing to
the diversity of their expertise and the institutionsthat they represented, the panelists provided view-
points from the perspective of a variety of relevant
stakeholders. Expert panelists represented the follow-
ing categories:
 6 participants representing 5 academic medical
centers (University of Washington, University of
Washington Medical Center, Arizona CERT,
Columbia University, and Erasmus University
Medical Center)
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vendors (Thompson Reuters, Wolters Kluwer,
Cerner Multum, First Data Bank and Lexi-Comp)
 2 participants representing 2 organizations with in-
house medical knowledge base maintenance and
development (Partners Healthcare and the Veterans
Administration)
 2 participants representing federal or private
agencies involved in the regulation of medication
use (The Food and Drug Administration (FDA) and
The American Society of Health-System Pharmacists
(ASHP))
In addition, we conducted individual phone calls with
representatives from the three leading medication know-
ledge base (KB) vendors [Cerner Multum, First Databank,
and Wolters Kluwer]. These phone calls provided in-
depth discussion of the criteria identified via the literature
review but also allowed discussion of practical consider-
ations for the use of these criteria by knowledge base ven-
dors in assessing DDIs. Additionally, the expert panel was
provided the opportunity to discuss the criteria using an
online portal called eRoom (EMC, version 7). An example
of the discussion between expert panelists on the criteria
of the ‘Evidence supporting the interaction’ is illustrated in
Figure 2. Names associated with specific comments
have been hidden to maintain the anonymity of the
contributors.
The conversations during the calls were recorded with
the permission of the participants and transcribed verba-
tim for analysis. Panelists were not provided anyFigure 2 Example of the discussion between expert panelists on the
associated with specific comments have been hidden to maintain the ano
discussion portal used by the expert panel for assessing criteria identified ffinancial incentive for participation and were chosen be-
cause of their expertise in the area of medication related
decision support, especially drug-drug interactions in
the context of use in medication knowledge bases for
CDS in EHR systems.
Results
The criteria identified from the systematic literature re-
view and validated with the panel are presented in Table 1.
These criteria represent what the literature indicates are
important considerations for how to choose which DDIs
to include in an EHR. In addition, by validating these cri-
teria with the medication knowledge base vendors we
were able to arrive on barriers for employing these criteria
and provide considerations for how they should be
employed in order to improve DDI alerting in EHRs.
The panel considered five criteria to be most import-
ant when assessing an interaction- Severity, Probability,
and Clinical Implications of the interaction, Patient char-
acteristics, and the Evidence supporting an interaction.
In order to further assess each criterion, there are sev-
eral sub-criteria that need to be taken into account.
Twenty-four sub-criteria were identified for the 5 cri-
teria: 4 for Severity of Interaction, 9 for Probability of
Interaction, 3 for Clinical Implications, 5 for Patient
characteristics, and 3 for Evidence Supporting the Inter-
action. We have listed these in Table 1 and identified the
citations from which the sub-criteria were derived. The
panel also identified barriers and considerations in order
to use these criteria in medication knowledge bases used
by EHRs, which are described in Table 2.criteria of the ‘Evidence Supporting the Interaction’. Names
nymity of the contributors. Provides a screenshot of the virtual
rom the literature review.
Table 1 Criteria for identifying clinically important drug-drug interactions for clinical decision support in electronic
health records
Criteria Description of the criteria and key sub-criteria that emerged from the literature review and expert panel
discussion
1. Severity of interaction [13-15] ■ Clinical Importance: Hansten, Horn and Hazlet in their ORCA classification identify clinical importance as a
function of both the inherent danger of the drug combination and the extent to which the presence of risk
factors predisposes the patient to the interaction. Also consideration of potential severity of the adverse
outcome (ORCA classification, Hansten, et al. [14])
■ Likelihood of Mortality
■ Likelihood of Morbidity
■ Likelihood of Intervention: The probability of the suggested intervention being able to prevent harm caused
by the interaction.
2. Probability of interaction
[13,14]
■ Likelihood of the Adverse Reaction
■ Timing of Administration
■ Consideration of the pharmacokinetic properties of the interaction: Some studies such as Siedling, et al. have
evaluated pharmacokinetic characteristics of DDIs between statins and various drugs. The study revealed that
more than half of the concentration-dependent ADEs related to statins were considered inappropriate if the
upper dose limits were taken into account.
■ Dose and Duration of Therapy
■ Route of Administration
■ Sequence of Administration
■ Monitoring planned for the patient
■ Therapeutic window of the object drug
■ Combination of drugs commonly used for therapeutic reasons
3. Clinical implications
[14,16-18]
■ Management burden: defined as the course of action a clinician may have to take for each potential drug
interaction
■ Monitoring planned for the interaction
■ Awareness of the intervention: Likelihood that providers may be aware of the ability to intervene in order to
prevent harm caused by an interaction.
4. Patient characteristics
[13,14,18]
■ Taking into account alcohol, diet, smoking and drug use which might alter the characteristics of the drug in
consideration resulting in possible DDIs.
■ Importance of age
■ Importance of gender
■ Concurrent diseases
■ Other active medications on the patient's profile
5. Evidence supporting
interaction [13-15,19-21]
■ Quantity of evidence: Adequacy of documentation in the literature
■ Quality of evidence: Association of the evidence with the study design and source of evidence. For example,
randomized trials can be rated as providing high quality evidence and observational studies or case reports as
low quality evidence.
■ Biological plausibility: Causal association as supported by medical evidence
Provides a descriptive representation of the criteria used to identify clinically important drug-drug interactions. This list focused on five categories, which include
Severity of interaction, Probability of interaction, Clinical implications, Patient characteristics, and Evidence supporting interaction.
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Severity of the interaction
Tiering alerts on the basis of severity is one of the most
important measure to reduce alert overriding and was
discussed in detail [26]. Experts agreed that severity of the
interaction should primarily be related to the risk/benefit
of using the drug pair concomitantly. Weighing the poten-
tial benefit would require careful consideration of patient
and disease characteristics. Clinical information thatprovides context for an interaction is not readily available
to knowledge base vendors thus their assessment of inter-
actions accounts for generic situations rather than specific
patient variables. In addition to the assessment of the risk/
benefit based on clinical context, one panelist opined
that when easy to use alternatives are available, one ac-
cepts less risk and therefore "severity" for such an
interaction should be greater. More research is needed
to understand this variation for assessing the severity
of an interaction.
Table 2 Barriers and considerations for including clinically important drug-drug interactions (DDIs) in electronic health
records (EHRs)
Barriers for the use of standardized criteria for
identifying DDIs for use in EHRs
Considerations suggested by the expert panel
1. Large disparities between drug knowledge bases
and among local experts [22,23]
The overlap between what is deemed as clinically significant by different knowledge bases is
low. Besides the disparity across databases there is often disagreement among local experts
(depending on clinical expertise and role) on the list of critically important DDIs.
2. Resource intensive process The process of conducting literature reviews and vetting them with users of the EHR is a
resource intensive process. Not all organizations have the ability to expend clinical resources
in order to customize their knowledge bases from a commercially supplied DDI set. The
knowledge management committee might need to re-evaluate the customized DDI set at
the time of every update provided by the vendor.
3. Need for ongoing review The list of clinically significant DDIs must be reviewed periodically in order to keep the
knowledge base current. This involves conducting ongoing literature reviews to assess
whether the evidence surrounding a DDI has changed since the time it was first assessed as
critically important.
4. Lack of context of patient populations [24] Knowledge base vendors lack the ability to contextualize DDIs based on the specific patient
populations where the EMR is used. Some guidelines can be provided in order to improve
specificity (e.g. for a geriatric population) however the use of these guidelines is limited and
dependent on the clinical practice where the EMR is implemented.
5. Inability to alert on DDIs caused by discontinuation
of drugs [25]
DDI alerts are based on drugs that are co-prescribed or administered together. Knowledge
base vendors are unable to provide DDI alerts for an interaction that may be caused by the
discontinuation of a drug. For example, the drug combination of clonidine and propranolol
where the discontinuation of clonidine from combined therapy with propranolol may
produce elevation of blood pressure.
6. Close integration with patient data in EMR Several patient characteristics play an important role in being able to identify the set of
clinically significant DDIs. While these patient characteristics, such as age, gender, or specific
lab values, are known to knowledge base providers they cannot be readily implemented
because these require close integration with the EHR in which the knowledge base is used.
Since KB vendors do not have control over the use, expression or standardization of these
data elements, their consideration in filtering the list of DDIs is limited.
7. Implementation of strategies to reduce “alert
fatigue” based on physician responses
One mechanism of reducing "alert fatigue" is taking into account previous responses of the
user to an alert. For example, if a physician has already seen an alert for a DDI should the
same alert be shown upon renewal of the medication? Additionally, if a physician has
previously determined a particular drug combination to be appropriate for a patient then
should he/she be re-alerted when renewing the drug combination for the same patient? The
inability to account for physician responses limits KB vendors from providing solutions that
take into account provider responses in the EHR system.
8. Customizing DDI list based on clinical workflow Consideration of the clinical workflow can also help streamline the alerts seen by clinicians.
For example, certain DDI alerts can be shown only to nurses since these would occur only if
the administration times of the medications were close together or where the sequence of
administration of the drugs is important. In this scenario, the physician need not be alerted. It
is difficult for knowledge base providers to implement such mechanisms of streamlining the
sub-set of DDIs shown to specific providers.
9. Software sophistication The sophistication of the software necessary to implement a DDI into a CDS system that also
considers patient information i.e. lab results is a challenge when it comes to space and the
upkeep necessary to such a system.
Provides a descriptive representation of the barriers associated with including clinically important drug-drug interactions. This list focused on nine categories,
which include Disparities between knowledge bases and local experts; Resource intensive process, Need for ongoing review, Lack of context of patient
populations, Inability to alert on DDIs caused by discontinuation of drugs, Close integration with patient data, Implementation of strategies to reduce alert fatigue,
Customizing DDI list based on clinical workflow, and Software sophistication.
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of severity should exist, the literature review showed that
there is no clear consensus on class designation and ter-
minology. There is also a lack of a developed taxonomy
for stratifying drug-drug interaction alerts, although a
five-category operational classification has been suggested
[13]. The Veterans Administration system classifies DDIs
as “critical” or “significant,” [27] while First DataBank
identifies three levels of DDIs- “contraindicated”, “severe”,
and “moderate” [28]. This is much larger than a problemof semantics since the interpretation of these labels varies
and no clear definitions exist on how DDIs fit into one
category versus another. While some medication know-
ledge base vendors do have clear definitions, these distinc-
tions are seldom obvious or available to the end-user who
is presented with the interactions.
Probability of the interaction
According to the panelists the likelihood of causing
harm is just as important as severity. However, it is
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patient context. In order to assess the likelihood of an
adverse drug event (ADE), panelists suggested including
the concentration response curve for the ADE of interest.
This is especially important when the ADE is unrelated to
the desired pharmacologic outcome, e.g., seizures caused
by the use of an analgesic such as meperidine [29]. Con-
sideration of the timing of administration is also import-
ant in determining whether an interaction would actually
take place. By adjusting the administration times in the
medication administration record to account for the half
lives of the drugs, a time-dependent drug-drug interaction
can be prevented. For example, the interaction between
quinolones and multivalent cations, resulting in the de-
creased absorption of the former, can be avoided by a rule
requiring separation in administering the drugs [30,31].
The formulation of the drug should be considered as an-
other sub-criterion to rule out those which occur due to
specific inactive ingredients present in certain formula-
tions, e.g. alcohol, which can interfere with the release
mechanism of sustained-release morphine causing too
much of the drug to be released rapidly resulting a poten-
tially fatal dose. In addition, the pharmacokinetic proper-
ties of the drugs should also be evaluated to rule out
presentation of inappropriate alerts. Seidling, et al. evalu-
ated 73 high risk statin-drug combinations for their phar-
macokinetic properties and concluded that more than half
of the DDI alerts that presented in a clinical decision sup-
port system were inappropriate since the DDI-specific
upper dose limits were not taken into account [32].
Clinical implications of the interaction
Panelists suggested consideration of the management
burden of the interaction, the monitoring planned and
the awareness of the provider regarding the interaction.
Management burden is defined as the course of action a
clinician may have to take for each potential drug inter-
action. Hansten and Horn describe three types of
actions- a. considering alternative drugs that may be less
likely to interact and thus avoiding the interaction b.
circumventing the interaction by minimizing the conse-
quence of the interaction and c. monitoring the patient
to detect the consequence of the interaction and minim-
izing the adverse outcome. For example the interaction
between the aripiprazole, a drug used for the treatment
of the symptoms of schizophrenia, and the antiarrhyth-
mic agent, amiodarone can be managed in three ways.
First, since the interaction occurs due to amiodarone’s
ability to inhibit the enzyme CYP3A4 responsible for the
metabolism of aripiprazole, another anti-arrhythmic
agent which does not display this inhibitory effect,
should be considered. For example, calcium, channel
blockers other than diltiazem and verapamil are unlikely
to inhibit CYP3A4. Second, if the provider decides toco-prescribe the two drugs, the dose of aripiprazole
should be reduced to one-half of the usual dose and if the
inhibitor is subsequently withdrawn then the dose should
be adjusted back to the usual dose. In addition, the patient
should be carefully monitored for aripiprazole-related ad-
verse reactions, such as shaking, vomiting or confusion
and alter the dose if such effects are observed. Third,
monitoring of the plasma concentration of aripiprazole is
also recommended when used in combination with
amiodarone [33]. Previous research conducted by Hines
and Warholak on DDI alerts seen in pharmacy informa-
tion systems, showed that over 35% of the systems evalu-
ated in the study, did not provide strategies for managing
an interaction [34]. This is an important piece of informa-
tion that allows the clinician to make the right decision
based on patient context. In the absence of information
on clinical consequence of co-prescribing two interacting
drugs providers would not be able to gauge the severity of
the interaction as it relates to a specific patient.
Patient characteristics
Specificity of alerting can be improved by developing
rules that take into account patient specific data. This
can be achieved by close integration between the medi-
cation knowledge base and the EHR. By extracting pa-
tient specific variables from the EHR, the alert will be
more meaningful and allow the physician to only see
alerts relevant to the patient at hand. For example, ac-
counting for the glomerular filteration rate or the cre-
atinine clearance to check for compromised kidney
function or the potassium level would be relevant before
firing an alert for an interaction between an antihyperten-
sive medication such as a beta blocker (labetalol and
metoprolol) and an angiotensin converting enzyme inhibi-
tor (lisinopril, enalopril and captopril) [35]. According to
Krall et al. [16]. the CDS should also allow rapid and easy
updates to a patient’s information to ensure continuous
relevant alerts as per their condition [36]. In future, when
EHRs are more mature in handling genetic characteristics,
these could also be accounted for in further improving the
specificity of the alerts fired for a patient. Medication
knowledge base vendors pointed out that estimating likeli-
hood of an interaction in the general population is already
hard, thus to write executable rules which take into ac-
count patient characteristics listed would be even more
challenging and expensive, though it may be feasible in
the future. Further, existing gaps in terminology and
standardization of knowledge representation along with
absent context specific algorithms make connections be-
tween the KB and the EHR difficult to achieve currently.
In light of these difficulties it was suggested that either the
corresponding alert text should mention some of these
pieces of information or the information should be made
available on demand (e.g., by providing a link) [37]. The
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the main message of the alert and brief so that it can be
easily interpreted or ignored when not needed.
Evidence supporting an interaction
The quantity and quality of the evidence associated with
an interaction which relates to the adequacy of its docu-
mentation and the study design and source of evidence
should be carefully assessed. In terms of study design,
randomized trials can be rated as providing high quality
evidence and observational studies or case reports as
low quality evidence. Further, several studies have cited
the limitations of relying on product labels as the source
of the evidence. Product labels are often over inclusive
and may result in over inclusion of interactions that may
not necessarily be clinically proven. Assessment of pri-
mary and secondary sources of literature, such as, the
U.S. Food and Drug Administration (FDA) Adverse
Event Reporting System (AERS) database of spontan-
eous adverse event reports should be included when
assessing the evidence associated with an interaction.
Seidling, et al. compared the dosage recommendations
provided in product labels and found that dosage rec-
ommendations for specific DDIs are seldom provided
in the drug label. When these authors evaluated the ef-
fect of the upper dose limits recommended in the drug
labels on the frequency of alerts, they found that fol-
lowing recommendations from the published literature
rather than the product labels could reduce the alert
frequency by 55% [32]. Rigorous study designs offer
better quality in making conclusions regarding an
interaction. One study assessing the interaction be-
tween warfarin and acetaminophen described how obser-
vational studies were insufficient to make conclusions
given the nonprescription or “over-the-counter” status of
acetaminophen [38]. Thus, randomized studies allowed
for the assessment of the temporal relationship, measur-
able effect with de-challenge and re-challenge, dose re-
sponse, exclusion or accounting of other possible etiologic
factors, and biological plausibility. Panelists pointed out
the limitations in the existence of randomized trials for
every member in a class of drugs thus resulting in ex-
trapolation across a class rather than specific assessment
to ascertain the biological plausibility of the interaction for
each member within the class. Gold standard studies do
not exist and quantity of evidence is sometimes limited to
case reports and not controlled studies. KB vendors iden-
tified that there is limited availability of primary literature
to assess the likelihood of an interaction compelling them
to rely on package inserts which are inaccurate, have large
inconsistencies across countries, out-dated and do not
always match with the medical literature. The panel
suggested that information from FDA, international
regulatory agencies and treatment guidelines are agood resource for confirming if drugs are safe to co-
prescribe. Providing this information in an abbreviated
manner within the alert rather than expecting the
provider to read the resources at the time of clinical
decision making, would also improve assessment of
the evidence in order to make appropriate therapeutic
decisions regarding a DDI.
Discussion
Current medication knowledge bases have overly sensi-
tive rules causing excessive alerts and several design and
implementation methods can be taken to reduce the
number of disruptive alerts. Using a two pronged ap-
proach using a literature review and then validating the
findings with an expert panel brought deep insight on
various criteria that need to be considered identifying
critical DDIs for use in EHRs.
Consideration of patient characteristics in combination
with drug characteristics (called probability of an inter-
action) by far represented the most important criteria.
The interplay between these two criteria provided a
good risk assessment of the interaction. Panelists sug-
gested several physician related strategies for reducing
alert fatigue, such as assessing physician’s previous
responses to the alert, consideration of the workflow and
customizing alerts based on physician practice, know-
ledge and comfort level [39]. Another suggestion was
the suppression of DDI alerts for drugs within order sets
and treatment guidelines since the appropriateness for
these would have been agreed upon previously by physi-
cians. However the panel agreed that limiting certain
levels of alerts to physicians was not a good idea and not
showing the same alerts to pharmacists and physicians
may create challenges in communication. They felt that
management options, including monitoring approaches,
do not change the significance of a potential interaction,
for, in spite of overriding an alert the clinician might
actually take relevant clinical or biochemical monitoring
measures. Thus, they believed that this information
should be included in the alert message but should not
be used to determine the severity of the interaction.
The panel felt that periodic reviews are important as
they would result in addition of new alerts and adjust-
ment of previous alerts, based on alert action data, as
new evidence regarding drugs becomes available or new
drugs enter the market. They also acknowledge that
such quality improvement efforts for the maintenance of
a knowledge base required a considerable undertaking
and was a highly resource intensive process. Panelists
discussed the KB developed in the Netherlands by The
Royal Dutch Association for the Advancement of Phar-
macy as an example of a nationally implemented KB and
advised others to leverage their work in order to
decrease the labor needed to create such a list [40].
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the relevance of the risk of the DDI in the specific
patient context. While this information regarding the pa-
tient characteristics relevant to a DDI is readily available,
several barriers exist in not being able to readily adopt it
in the context of improving alert specificity. Some ven-
dors described their frustration at the lack of support
from EMR vendors or hospital sites in the implementa-
tion of the patient contextualized logic used for DDI
alerting. Since integration of patient characteristics in
the CDS system is a resource intensive process and we
do not have adequate technological support to incorpor-
ate these additional features this parameter should be
considered for development of more sophisticated deci-
sion support systems in the future.
Another barrier is the lack of standardization of defini-
tions due to localized definitions and customized ranges
used by providers. For example, if a certain interaction
was relevant only in the context of patients with renal
failure then KB vendors need a standardized definition
of what is meant by “renal failure” so that this logic can
be programmatically implemented. Clinicians vary in
their interpretations of this logic and often localization
of such clinical definitions inhibits the incorporation of
such logic into decision support rules. Further, even if
there were standardization of such logic, its incorpor-
ation in the knowledge base would require strong link-
age between the EHR and the KB to combine the
relevant data and logic to make a refined, patient-
specific recommendation, though such linkages have
many benefits [41]. In an environment where the above
barriers exist, participants suggested that key pieces of
information should be included in the textual informa-
tion contained in an alert at least initially.
The second criterion which was considered most im-
portant was an understanding of the drug characteris-
tics, which we called the “probability of the interaction”
in our discussion. This criterion takes into account con-
siderations of the duration of therapy, dosage, route,
regimen, etc. Similar to patient characteristics, informa-
tion about the influence of specific drug or regimen
characteristics is available in medication knowledge
bases but has not been readily implemented in the deci-
sion support systems. Participants discussed ways this
information could be employed more effectively, such
as, the timing, formulation and sequence of administra-
tion could be considered within the realm of the medica-
tion administration record. For example, an interaction
between itraconazole with proton pump inhibitors
occurs in capsule form but not the solution. Thus, in
this example, in the context of an order entry system,
a provider who chooses the solution should not re-
ceive the alert whereas the provider who chooses the
capsule should.The consideration of the context of the setting is im-
portant as availability of facilities for monitoring such as
anticoagulation clinics, etc. could further lower the prob-
ability that a patient would actually have the interaction.
Thus, allowing healthcare institutions or providers to ma-
nipulate the level of the interaction based on the consider-
ation of the setting could provide another mechanism for
assessing the priority of an interaction, though this may
not be practical in the near term.
Lastly, development of a standardized scale with trans-
parent criteria or editorial guidelines for evaluation of
the evidence related to an interaction is needed. One ex-
ample was the work that has been undertaken in the
Netherlands where articles are categorized on a scale
that allows scoring the evidence using explicit criteria.
The scale also allows for coding extrapolated evidence in
a manner that is distinguishable from evidence that has
been gathered from empirical data. This allows transpar-
ency into the scoring of the evidence and uniformity for
comparison for the adjudication of the level of an alert.
When there is a lack of reliable clinical evidence related
to an interaction, participants suggested consideration of
the likelihood of an interaction based on the pharmaco-
dynamic and pharmacokinetic properties. The value of
quantity of evidence was undermined in light of such a
consideration. Added to this discussion were the consid-
eration of a pharmacologic mechanism class rather than
the simplistic concept of a drug class. This would allow
consideration of the pharmacokinetic properties to de-
termine possible interactions even in the absence of
published evidence (i.e. biological plausibility).
Conclusions
This study describes the complexity of assessing DDIs for
clinical decision support in EHRs. This is a first attempt to
provide a comprehensive assessment of the literature and
validate the criteria with an expert panel of knowledge base
vendors. This approach enabled the insights discussed in
the study to be pragmatic solutions for overcoming
existing barriers to improve the specificity of DDI alerts in
EHRs. While this represents a first step in identifying cri-
teria and barriers for evaluating critical DDIs, future
research is needed to develop standardized editorial
guidelines for uniform adoption of these criteria across
medication knowledge bases in EHRs.
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